Key Takeaways
- India-EU Free Trade Agreement (FTA) is projected to take effect by Q1 2027, following nearly two decades of negotiations and a formal conclusion earlier this year.
- Societe Generale (GLE) unveiled a strategic roadmap for 2029, targeting €1.9 billion in gross savings and a 30% reduction in IT costs since 2022.
- Novo Nordisk (NVO) reached 7 million prescriptions for its Wegovy pill in the U.S. while announcing an additional 4,000 job cuts, bringing its total downsizing to 13,000 individuals.
- India and Canada will resume high-level trade talks on October 5, 2026, aiming to finalize a Comprehensive Economic Partnership Agreement (CEPA) by the end of the year.
India Accelerates Trade Alliances with EU and Canada
India is entering a critical phase of trade diplomacy as it moves to operationalize major agreements with the European Union and Canada. Commerce Minister Piyush Goyal announced on Monday that the India-EU FTA is expected to become effective within the next 6 to 7 months, marking a historic shift for Indian exports. The deal is set to eliminate or reduce tariffs on 96% of EU goods exports to India, potentially saving European businesses approximately €4 billion annually in duties.
Simultaneously, India and Canada are scheduled to hold their next round of trade negotiations starting October 5. Both nations have reaffirmed a commitment to conclude the Comprehensive Economic Partnership Agreement (CEPA) by the end of 2026. This agreement aims to more than double bilateral trade from $30.4 billion to $70 billion by 2030, focusing on critical sectors such as AI, clean energy, and critical minerals.
Societe Generale Targets Efficiency and AI-Driven Savings
Societe Generale (GLE) CEO Slawomir Krupa has placed cost discipline at the center of the bank’s 2029 strategic plan. The French lender aims to reduce its cost-to-income ratio to below 55% by 2029, down from its current 60% target. A significant portion of these efficiencies will stem from a 30% reduction in IT costs compared to 2022 levels, driven by the decommissioning of legacy systems and the integration of Artificial Intelligence (AI).
The bank expects to achieve €1.9 billion in gross savings by 2029 through procurement optimization and natural staff attrition. Krupa’s roadmap also includes ambitious financial targets, such as a Return on Tangible Equity (ROTE) of 13% to 14% by 2029. Investors responded positively to the clarity on capital returns, as the bank signaled potential shareholder payouts of up to €21 billion in dividends and buybacks over the four-year period.
Novo Nordisk Diversifies Beyond Obesity Blockbusters
Despite the massive success of its weight-loss drug Wegovy, Novo Nordisk (NVO) is aggressively diversifying its portfolio to mitigate future patent expiries. CEO Mike Doustdar identified liver disease and cardiovascular health as primary expansion areas. The company is also establishing a new segment dedicated to Blood and Endocrine Disorders to broaden its clinical profile beyond its core diabetes and obesity franchises.
The company continues to see robust demand in the U.S., where the Wegovy pill has surpassed 7 million prescriptions. However, the operational unification of the company has led to significant corporate downsizing. An additional 4,000 personnel are slated to leave the company, bringing the total workforce reduction to 13,000 individuals. This restructuring is part of a broader effort to save approximately $1.3 billion annually and reinvest those funds into next-generation R&D.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.